NO20033399L - Eterderivater anvendelige som inhibitorer av PDE4-isoenzymer - Google Patents

Eterderivater anvendelige som inhibitorer av PDE4-isoenzymer

Info

Publication number: NO20033399L
Authority: NO; Norway
Prior art keywords: inhibitors; ether derivatives; derivatives useful; pde4 isoenzymes; isoenzymes
Prior art date: 2001-01-31

Application number

NO20033399A

Other languages

English (en)

Other versions

NO20033399D0 (no

Inventor

Robert James Chambers

Thomas Victor Magee

Anthony Marfat

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-31

Filing date

2003-07-30

Publication date

2003-09-25

2003-07-30 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-07-30 Publication of NO20033399D0 publication Critical patent/NO20033399D0/no

2003-09-25 Publication of NO20033399L publication Critical patent/NO20033399L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Oncology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Diabetes (AREA)
Virology (AREA)
Hematology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Biomedical Technology (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20033399A 2001-01-31 2003-07-30 Eterderivater anvendelige som inhibitorer av PDE4-isoenzymer NO20033399L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US26530401P	2001-01-31	2001-01-31
PCT/IB2001/002726 WO2002060896A1 (en)	2001-01-31	2001-12-24	Ether derivatives useful as inhibitors of pde4 isozymes

Publications (2)

Publication Number	Publication Date
NO20033399D0 NO20033399D0 (no)	2003-07-30
NO20033399L true NO20033399L (no)	2003-09-25

Family

ID=23009905

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20033399A NO20033399L (no)	2001-01-31	2003-07-30	Eterderivater anvendelige som inhibitorer av PDE4-isoenzymer

Country Status (34)

Country	Link
US (3)	US6828333B2 (no)
EP (1)	EP1373258B1 (no)
JP (1)	JP2004518689A (no)
KR (1)	KR20030070150A (no)
CN (1)	CN1527830A (no)
AP (1)	AP2002002415A0 (no)
AR (1)	AR032522A1 (no)
AT (1)	ATE305467T1 (no)
BG (1)	BG107960A (no)
BR (1)	BR0116845A (no)
CA (1)	CA2436544A1 (no)
CR (1)	CR7043A (no)
CZ (1)	CZ20031902A3 (no)
DE (1)	DE60113731T2 (no)
EA (1)	EA200300652A1 (no)
EE (1)	EE200300361A (no)
ES (1)	ES2248231T3 (no)
GT (1)	GT200200012A (no)
HU (1)	HUP0302891A2 (no)
IL (1)	IL156460A0 (no)
IS (1)	IS6847A (no)
MA (1)	MA26984A1 (no)
MX (1)	MXPA03006885A (no)
NO (1)	NO20033399L (no)
NZ (1)	NZ526531A (no)
OA (1)	OA12541A (no)
PA (1)	PA8537901A1 (no)
PE (1)	PE20020846A1 (no)
PL (1)	PL364910A1 (no)
SK (1)	SK8942003A3 (no)
SV (1)	SV2003000861A (no)
TN (1)	TNSN03051A1 (no)
WO (1)	WO2002060896A1 (no)
ZA (1)	ZA200304893B (no)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ20031902A3 (cs) *	2001-01-31	2004-07-14	Pfizer Products Inc.	Etherové deriváty užitečné jako inhibitory isozymů PDE4
US20030055026A1 (en)	2001-04-17	2003-03-20	Dey L.P.	Formoterol/steroid bronchodilating compositions and methods of use thereof
US6777432B1 (en) *	2001-09-04	2004-08-17	Darwin Molecular Corporation	Pharmaceutical uses and synthesis of nicotinamides
IL160271A0 (en)	2001-09-19	2004-07-25	Altana Pharma Ag	Pharmaceutical compositions containing pde4-inhibitors and nsaid
US20050158371A1 (en) *	2002-02-12	2005-07-21	Sumitomo Pharmaceuticals Co., Ltd.	Novel external agent
JP2006516548A (ja)	2002-12-30	2006-07-06	アンジオテックインターナショナルアクツィエンゲゼルシャフト	迅速ゲル化ポリマー組成物からの薬物送達法
WO2004067006A1 (en) *	2003-01-27	2004-08-12	Pharmacia Corporation	Combination of a pde iv inhibitor and a tnf-alpha antagonist
TWI359675B (en)	2003-07-10	2012-03-11	Dey L P	Bronchodilating β-agonist compositions
US20050186276A1 (en) *	2003-07-17	2005-08-25	Pfizer Inc	Pharmaceutical formulations
GB0317484D0 (en)	2003-07-25	2003-08-27	Pfizer Ltd	Nicotinamide derivatives useful as pde4 inhibitors
US7132435B2 (en)	2003-07-25	2006-11-07	Pfizer Inc.	Compounds
GB0317471D0 (en) *	2003-07-25	2003-08-27	Pfizer Ltd	Novel compounds
GB0317516D0 (en)	2003-07-25	2003-08-27	Pfizer Ltd	Nicotinamide derivatives useful as PDE4 inhibitors
US7153870B2 (en)	2003-07-25	2006-12-26	Pfizer Inc.	Nicotinamide derivatives useful as PDE4 inhibitors
US20050187278A1 (en) *	2003-08-28	2005-08-25	Pharmacia Corporation	Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
US7776893B2 (en) *	2003-09-05	2010-08-17	Nycomed Gmbh	Use of PDE4 inhibitors for the treatment of diabetes mellitus
JP3997255B2 (ja)	2004-02-13	2007-10-24	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	アンドロゲンレセプターモジュレーター
WO2005100305A1 (en) *	2004-04-13	2005-10-27	Warner-Lambert Company Llc	Androgen modulators
WO2005102990A1 (en)	2004-04-22	2005-11-03	Warner-Lambert Company Llc	Androgen modulators
BRPI0513020A (pt)	2004-07-08	2008-04-22	Warner Lambert Co	moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação
WO2006094942A1 (en) *	2005-03-08	2006-09-14	Nycomed Gmbh	Roflumilast for the treatment of diabetes mellitus
NZ560269A (en) *	2005-03-08	2010-12-24	Nycomed Gmbh	Roflumilast for the treatment of diabetes mellitus
RS52944B (sr) *	2005-04-19	2014-02-28	Takeda Gmbh	Roflumilast za lečenje pulmonarne hipertenzije
TW200724139A (en)	2005-05-05	2007-07-01	Warner Lambert Co	Androgen modulators
CA2620333A1 (en)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en)	2005-10-31	2011-04-27	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
TWI385169B (zh)	2005-10-31	2013-02-11	Eisai R&D Man Co Ltd	經雜環取代之吡啶衍生物及含有彼之抗真菌劑
KR20080065704A (ko)	2005-11-09	2008-07-14	콤비네이토릭스, 인코포레이티드	의학적 이상의 치료 방법들, 조성물들, 및 키트들
JP2009524590A (ja) *	2005-12-20	2009-07-02	ティカレーケメデルアーベー	薬物動態学的プロフィールの向上を有するコルチコステロイドを送達するための方法およびシステム
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2021000A2 (en)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenesis by modulating angiotensin
JP2009536667A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	５ｈｔ受容体介在性の神経新生
MX2009002496A (es)	2006-09-08	2009-07-10	Braincells Inc	Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
US8513287B2 (en)	2007-12-27	2013-08-20	Eisai R&D Management Co., Ltd.	Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US8569229B2 (en) *	2008-02-07	2013-10-29	The Children's Hospital Of Philadelphia	Compositions and methods which modulate G-protein signaling for the treatment of inflammatory disorders such as asthma and allergic conjunctivitis
RU2011108587A (ru)	2008-08-05	2012-09-10	Те Огайо Стейт Юниверсити Рисерч Фаундейшн (Us)	Новые метилендиоксифенольные соединения и их применение для лечения заболеваний
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
US8728516B2 (en) *	2009-04-30	2014-05-20	Abbvie Inc.	Stabilized lipid formulation of apoptosis promoter
US20100280031A1 (en) *	2009-04-30	2010-11-04	Paul David	Lipid formulation of apoptosis promoter
SG176571A1 (en) *	2009-05-19	2012-01-30	Vivia Biotech Sl	Methods for providing personalized medicine tests ex vivo for hematological neoplasms
TWI532484B (zh) *	2009-06-08	2016-05-11	艾伯維有限公司	包含凋亡促進劑之固態分散劑
TWI471321B (zh) *	2009-06-08	2015-02-01	亞培公司	Ｂｃｌ－２族群抑制劑之口服醫藥劑型
US8697691B2 (en) *	2009-12-21	2014-04-15	Vanderbilt University	Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same
SG10201500152UA (en) *	2009-12-22	2015-03-30	Abbvie Inc	Abt-263 capsule
UA113500C2 (xx)	2010-10-29	2017-02-10		Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
WO2013106547A1 (en)	2012-01-10	2013-07-18	President And Fellows Of Harvard College	Beta-cell replication promoting compounds and methods of their use
US9433680B2 (en)	2013-01-31	2016-09-06	Merz Pharmaceuticals, Llc	Topical compositions and methods for making and using same
US9446131B2 (en)	2013-01-31	2016-09-20	Merz Pharmaceuticals, Llc	Topical compositions and methods for making and using same
US8778365B1 (en)	2013-01-31	2014-07-15	Merz Pharmaceuticals, Llc	Topical compositions and methods for making and using same
US9452173B2 (en)	2013-01-31	2016-09-27	Merz Pharmaceuticals, Llc	Topical compositions and methods for making and using same
EP3039126B1 (en)	2013-08-26	2019-10-09	The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone	Small molecule cellular reprogramming to generate neuronal cells
CN108299418A (zh) *	2017-09-14	2018-07-20	刘双伟	一种抗过敏和哮喘的噻唑基烟酰胺类化合物的合成方法
US11174220B2 (en)	2019-12-13	2021-11-16	Inspirna, Inc.	Metal salts and uses thereof
IT201900025126A1 (it) *	2019-12-20	2021-06-20	Sildeha Swiss S A	Uso di derivati dell’acido ialuronico nella rigenerazione dei tessuti ossei e cartilaginei
US11116737B1 (en)	2020-04-10	2021-09-14	University Of Georgia Research Foundation, Inc.	Methods of using probenecid for treatment of coronavirus infections
KR102404883B1 (ko)	2020-11-30	2022-06-07	(주)이노보테라퓨틱스	벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물
CN114907315B (zh) *	2022-05-17	2023-09-12	重庆医科大学	Selitrectinib中间体的合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2140772A5 (en)	1971-06-07	1973-01-19	Aries Robert	Phenoxynicotinoylaminophenols - analgesics tranquillisers antipyretics, anti-inflammatories and antirheumatics
US4270946A (en) *	1979-10-01	1981-06-02	Stauffer Chemical Company	N-Aryl,2-phenoxy nicotinamide compounds and the herbicidal use thereof
US4692185A (en) *	1986-01-13	1987-09-08	Stauffer Chemical Company	N-(ortho-substituted) benzyl, 3-trifluoromethylphenoxy nicotinamides as herbicides
US4861891A (en)	1988-08-31	1989-08-29	Pfizer Inc.	Antidepressant N-substituted nicotinamide compounds
ATE174343T1 (de)	1991-02-27	1998-12-15	Lacer Sa	Antihypertensive n-(alpha-substituiertes pyridyl)-carbonyldipeptide
US5602438A (en) *	1991-02-28	1997-02-11	Robert Bosch Gmbh	Roll commutator for electric motors and dynamos, and method of manufacturing it
DE4200323A1 (de)	1992-01-09	1993-07-15	Bayer Ag	Herbizide und pflanzennematizide mittel auf basis von mercaptonicotinsaeurederivaten
EP0633776B1 (en)	1992-04-02	2001-05-09	Smithkline Beecham Corporation	Compounds useful for treating allergic and inflammatory diseases
EP0710109B1 (en)	1993-06-18	2004-09-15	Smithkline Beecham Corporation	Method for identifying a PDE IV inhibitor
JP3406689B2 (ja)	1994-03-15	2003-05-12	株式会社大塚製薬工場	ナフチリジン及びピリドピラジン誘導体
US5618027A (en) *	1994-07-20	1997-04-08	Nevrekar; Venkatesh R.	Gate valve
WO1996019990A1 (en)	1994-12-23	1996-07-04	Smithkline Beecham Corporation	4,4-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds
TW429148B (en) *	1995-10-27	2001-04-11	Pfizer	Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
EP0796619A1 (en) *	1996-03-21	1997-09-24	Merrell Pharmaceuticals Inc.	Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
FR2754178B1 (fr) *	1996-10-04	2002-08-23	Adir	Utilisation de la sulbutiamine pour l'obtention de compositions pharmaceutiques utiles dans le traitement de certains troubles psychomoteurs et psycho-intellectuels
GB9622386D0 (en)	1996-10-28	1997-01-08	Sandoz Ltd	Organic compounds
US5922557A (en)	1997-01-09	1999-07-13	Merck & Co., Inc.	System for stably expressing a high-affinity camp phosphodiesterase and use thereof
TR200001847T2 (tr)	1997-04-04	2002-06-21	Pfizer Products Inc.	Nikotinamid Türevleri
GB9715584D0 (en) *	1997-07-23	1997-10-01	Eisai Co Ltd	Compounds
UA67753C2 (uk)	1997-10-10	2004-07-15	Смітклайн Бічам Корпорейшн	Спосіб отримання заміщених 4-феніл-4-ціанциклогексанових кислот
AR015966A1 (es)	1997-10-17	2001-05-30	Smithkline Beecham Corp	Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
AR015190A1 (es)	1997-10-23	2001-04-18	Smithkline Beecham Corp	Un polimorfo cristalino de 1,3-diciclopropilmetil-8-aminoxantina, procedimiento para su preparacion, composiciones farmaceuticas que lo contienen y su usopara la manufactura de un medicamento
CA2398182C (en) *	2000-01-31	2007-03-13	Pfizer Products Inc.	Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
ATE269860T1 (de) *	2000-01-31	2004-07-15	Pfizer Prod Inc	Pyrimidinylcarboxamiden als inhibitoren der pde4 isoenzyme
CZ20031902A3 (cs) *	2001-01-31	2004-07-14	Pfizer Products Inc.	Etherové deriváty užitečné jako inhibitory isozymů PDE4

2001
- 2001-12-24 CZ CZ20031902A patent/CZ20031902A3/cs unknown
- 2001-12-24 EA EA200300652A patent/EA200300652A1/ru unknown
- 2001-12-24 CA CA002436544A patent/CA2436544A1/en not_active Abandoned
- 2001-12-24 JP JP2002561464A patent/JP2004518689A/ja active Pending
- 2001-12-24 MX MXPA03006885A patent/MXPA03006885A/es active IP Right Grant
- 2001-12-24 PL PL01364910A patent/PL364910A1/xx not_active Application Discontinuation
- 2001-12-24 NZ NZ526531A patent/NZ526531A/en unknown
- 2001-12-24 EP EP01273558A patent/EP1373258B1/en not_active Expired - Lifetime
- 2001-12-24 ES ES01273558T patent/ES2248231T3/es not_active Expired - Lifetime
- 2001-12-24 DE DE60113731T patent/DE60113731T2/de not_active Expired - Fee Related
- 2001-12-24 IL IL15646001A patent/IL156460A0/xx unknown
- 2001-12-24 KR KR10-2003-7010088A patent/KR20030070150A/ko not_active Ceased
- 2001-12-24 WO PCT/IB2001/002726 patent/WO2002060896A1/en not_active Ceased
- 2001-12-24 EE EEP200300361A patent/EE200300361A/xx unknown
- 2001-12-24 HU HU0302891A patent/HUP0302891A2/hu unknown
- 2001-12-24 SK SK8942003A patent/SK8942003A3/sk unknown
- 2001-12-24 BR BR0116845-2A patent/BR0116845A/pt not_active IP Right Cessation
- 2001-12-24 CN CNA018230989A patent/CN1527830A/zh active Pending
- 2001-12-24 OA OA1200300176A patent/OA12541A/en unknown
- 2001-12-24 AT AT01273558T patent/ATE305467T1/de not_active IP Right Cessation
2002
- 2002-01-28 GT GT200200012A patent/GT200200012A/es unknown
- 2002-01-29 PA PA20028537901A patent/PA8537901A1/es unknown
- 2002-01-29 AR ARP020100307A patent/AR032522A1/es unknown
- 2002-01-30 SV SV2002000861A patent/SV2003000861A/es not_active Application Discontinuation
- 2002-01-30 PE PE2002000070A patent/PE20020846A1/es not_active Application Discontinuation
- 2002-01-31 AP APAP/P/2002/002415A patent/AP2002002415A0/en unknown
- 2002-01-31 US US10/066,503 patent/US6828333B2/en not_active Expired - Fee Related
2003
- 2003-06-16 IS IS6847A patent/IS6847A/is unknown
- 2003-06-24 ZA ZA200304893A patent/ZA200304893B/xx unknown
- 2003-07-01 BG BG107960A patent/BG107960A/xx unknown
- 2003-07-08 TN TNPCT/IB2001/002726A patent/TNSN03051A1/fr unknown
- 2003-07-21 MA MA27242A patent/MA26984A1/fr unknown
- 2003-07-30 NO NO20033399A patent/NO20033399L/no not_active Application Discontinuation
- 2003-07-30 CR CR7043A patent/CR7043A/es unknown
2004
- 2004-08-13 US US10/918,820 patent/US7183293B2/en not_active Expired - Fee Related
2007
- 2007-01-30 US US11/668,915 patent/US20070161681A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BR0116845A (pt)	2004-02-25
CZ20031902A3 (cs)	2004-07-14
ZA200304893B (en)	2004-06-24
PA8537901A1 (es)	2002-10-31
HUP0302891A2 (hu)	2003-12-29
AR032522A1 (es)	2003-11-12
WO2002060896A1 (en)	2002-08-08
SV2003000861A (es)	2003-01-13
EA200300652A1 (ru)	2003-12-25
JP2004518689A (ja)	2004-06-24
CA2436544A1 (en)	2002-08-08
MXPA03006885A (es)	2003-11-13
US6828333B2 (en)	2004-12-07
AP2002002415A0 (en)	2002-03-31
OA12541A (en)	2006-06-05
NO20033399D0 (no)	2003-07-30
KR20030070150A (ko)	2003-08-27
PE20020846A1 (es)	2002-09-21
SK8942003A3 (en)	2004-10-05
US7183293B2 (en)	2007-02-27
EE200300361A (et)	2003-12-15
US20070161681A1 (en)	2007-07-12
MA26984A1 (fr)	2004-12-20
PL364910A1 (en)	2004-12-27
ES2248231T3 (es)	2006-03-16
DE60113731D1 (de)	2006-02-09
AU2002222428A2 (no)	2002-08-12
US20050049258A1 (en)	2005-03-03
IL156460A0 (en)	2004-01-04
CN1527830A (zh)	2004-09-08
EP1373258B1 (en)	2005-09-28
IS6847A (is)	2003-06-16
DE60113731T2 (de)	2006-06-29
BG107960A (en)	2004-10-29
CR7043A (es)	2003-11-25
TNSN03051A1 (fr)	2005-12-23
ATE305467T1 (de)	2005-10-15
US20030027845A1 (en)	2003-02-06
NZ526531A (en)	2005-02-25
GT200200012A (es)	2002-09-02
EP1373258A1 (en)	2004-01-02

Publication	Publication Date	Title
NO20033399L (no)	2003-09-25	Eterderivater anvendelige som inhibitorer av PDE4-isoenzymer
NO20023614L (no)	2002-09-30	Pyrimidin-karboksamider som er anvendelige som inhibitorer for PDE4-isoenzymer
NO20033397D0 (no)	2003-07-30	Nikotinamidbiarylderivater nyttige som inhibitorer av PDE4 isozymer
NO20043158L (no)	2004-09-16	Substituerte kinazolinderivater som inhibitorer av aurorakinaser
SE0701538L (sv)	2007-06-26	Azaspiroalkanderivat som hämmare av metalloproteaser
NO20043793L (no)	2004-10-21	Nikotinamidderivater anvendelige som PDE4 inhibitorer
NO20014837D0 (no)	2001-10-04	Pyrazolsammensetninger nyttige som inhibitorer av ERK
NO20041180L (no)	2004-03-19	Pyrrolopyrimidiner som midler for inbibering av cysteinprotaser
NO20023613D0 (no)	2002-07-30	Nikotinamid benzokondenserte heterocyclyl derivater nyttige som selektive inhibitorer av PDE4 isozymer
NO20023828L (no)	2002-09-30	Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
NO20030867L (no)	2003-02-25	Hydroksamderivater anvendelig som deacetylaseinhibitorer
NO20026262L (no)	2002-12-27	Cyklopentyl-substituerte glutaramidderivater som inhibitorer av nöytral endopeptidase
NO20043726L (no)	2004-11-08	Heteroarylforbindelser anvendelige som inhibitorer av GSK-3
NO20033593L (no)	2003-08-13	Kinazoliner som MMP-13 inhibitorer
NO20021042L (no)	2002-04-30	Benzofenoner som inhibitorer av reverstranskriptaser
DK1556375T3 (da)	2008-11-03	Flavonderivater som inhibitorer af cyklinafhængige kinaser
NO20033618D0 (no)	2003-08-14	Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
NO20025811D0 (no)	2002-12-03	Forbindelser som er effektive som beta-2-adrenoreseptor- anonister så vel som PDE4-inhibitorer
DK1401828T3 (da)	2006-07-31	N-Formylhydroxylaminforbindelser som inhibitorer af PDF
NO20021959D0 (no)	2002-04-25	Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
DK1651641T3 (da)	2007-09-03	Nicotinamidderivater egnede som PDE4 inhibitorer
NO20022123D0 (no)	2002-05-03	Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
NO20035206D0 (no)	2003-11-24	Pyrimidin-derivater anvendelige som selektive COX-2- inhibitorer
NO20030820D0 (no)	2003-02-21	Anvendelse av vitamin D derivater som benresorpsjons inhibitorer
DK1252158T3 (da)	2005-08-22	Benzo-annelleret heterocyclyl-nicotinamed-derivater, der er nyttige som selektive inhibitorer af PDE4-isozymer

Legal Events

Date	Code	Title	Description
2006-07-31	FC2A	Withdrawal, rejection or dismissal of laid open patent application